scorecardresearch
Follow Us:
Thursday, January 21, 2021

Bharat Biotech seeks emergency use authorisation for indigenously developed Covaxin

The applications of Bharat Biotech, Serum Institute of India and Pfizer will be reviewed by the subject expert committee on COVID-19 at the Central Drugs Standard Control Organisation on Wednesday, sources said.

By: PTI | New Delhi | Updated: December 7, 2020 11:49:33 pm
Covaxin, Bharat biotech, Anil vij tests positive, Anil Vij covaxin, Bharat biotech on Covaxin trials, Indida news, Coronavirus news, Indian expressRepresentational Image (File)

After Pfizer and Serum Institute, Hyderabad-based pharmaceutical firm Bharat Biotech on Monday applied to the central drug regulator seeking emergency use authorisation for its COVID-19 vaccine Covaxin, official sources said.

The applications of Bharat Biotech, Serum Institute of India and Pfizer will be reviewed by the subject expert committee (SEC) on COVID-19 at the Central Drugs Standard Control Organisation (CDSCO) on Wednesday, sources said.

Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

On December 4, Prime Minister Narendra Modi at an all-party meeting had expressed hope that a COVID-19 vaccine may be ready in a few weeks.

That same evening, the Indian arm of US pharmaceutical giant Pfizer sought emergency use approval for its vaccine from the central drug regulator, after the firm secured such clearance in the UK and Bahrain.

The Serum Institute sought such nod for the Oxford COVID-19 vaccine, Covishield, on December 6.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement